GlassScriptPhysician profile
Angel Vinuela
NPI 1508192881
$181,632.63
in general payments reported to CMS, 2019-2025
17 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $18K · 2021: $31K · 2022: $29K · 2023: $21K · 2024: $16K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $9,840 · Travel and Lodging: $5,031 · Food and Beverage: $4,841 · Education: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,132.50 |
| Consulting Fee | $9,840.00 |
| Travel and Lodging | $5,031.25 |
| Food and Beverage | $4,841.35 |
| Education | $1,011.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $43,697.78 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $38,802.53 | 2019-2025 | Botox, Duopa, Qulipta |
| Acadia Pharmaceuticals INC | $24,269.87 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $22,977.77 | 2019-2025 | Crexont, Rytary |
| Acorda Therapeutics, INC | $18,143.26 | 2019-2022 | |
| Allergan, INC. | $6,434.07 | 2019-2021 | |
| Mdd US Operations, LLC | $6,255.79 | 2022-2024 | Apokyn, Gocovri, Gocovri |
| Medtronic USA, INC. | $5,672.04 | 2019 | |
| Kyowa Kirin, INC. | $5,433.36 | 2019 | |
| Medtronic, INC. | $4,038.69 | 2019-2025 | Percept PC Brainsense, Inceptiv |
| Adamas Pharmaceuticals, INC. | $3,762.33 | 2020-2021 | |
| Abbott Laboratories | $1,615.56 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $318.87 | 2021-2022 | |
| Pbg Puerto Rico LLC | $110.39 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $65.13 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.31 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Vinuela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.